Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.

被引：0
|
作者：
Aapro, Matti S.
Demidchik, Yuri
Bondarenko, Igor
Siedakov, Igor
Sakaeva, Dina
Krishnamurthy, S.
Roman, Laslo
Lebedeva, Liudmila
Mefti, Fawzia
Ponomarova, Olga
Bachelot, Thomas Denis
Lytvyn, Lryna
Delaloge, Suzette
Kupp, Anita
Karchmit, Yauheniya
Bougnoux, Philippe
Campone, Mario
Martin, Miguel
机构：
[1] Clin Genolier, Genolier, Switzerland
[2] Belarusian Med Acad Postgrad Educ, Minsk, BELARUS
[3] Dnipropetrovsk City Multifield Clin Hosp 4, Dnepropetrovsk, Ukraine
[4] Reg Antitumor Ctr, Donetsk, Ukraine
[5] Republican Clin Oncol Dispensary, Ufa, Russia
[6] Kidway Mem Inst Oncol, Bangalore, Karnataka, India
[7] Leningrad Reg Oncol Dispensary, St Petersburg, Russia
[8] Clin Oncol Dispensary, Arkhangelsk, Russia
[9] Hop Rene Huguenin, Inst Curie, St Cloud, France
[10] City Oncol Hosp, Kiev, Ukraine
[11] Ctr Leon Berard, Dept Oncol Med, F-69373 Lyon, France
[12] Reg Oncol Hosp, Dnepropetrovsk, Ukraine
[13] Inst Cancerol Gustave Roussy, Villejuif, France
[14] North Estonia Med Ctr, Tallinn, Estonia
[15] Reg Clin Oncol Dispensary, Vitebsk, BELARUS
[16] CHU Bretonneau, Dept Med Oncol, F-37044 Tours, France
[17] Inst Cancerol Ouest, Nantes, France
[18] Hosp Univ Gregorio Maranon, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1013
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer
    Keun Seok Lee
    In Hae Park
    Byung-Ho Nam
    Jungsil Ro
    Investigational New Drugs, 2013, 31 : 152 - 159
  • [32] Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer
    Lee, Keun Seok
    Park, In Hae
    Nam, Byung-Ho
    Ro, Jungsil
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 152 - 159
  • [33] Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
    Thomas, Eva S.
    Gomez, Henry L.
    Li, Rubi K.
    Chung, Hyun-Cheol
    Fein, Luis E.
    Chan, Valorie F.
    Jassem, Jacek
    Pivot, Xavier B.
    Klimovsky, Judith V.
    de Mendoza, Fernando Hurtado
    Xu, Binghe
    Campone, Mario
    Lerzo, Guillermo L.
    Peck, Ronald A.
    Mukhopadhyay, Pralay
    Vahdat, Linda T.
    Roche, Henri H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5210 - 5217
  • [34] Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
    Thomas, Eva S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2223 - 2223
  • [35] Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC)
    Crown, J.
    Dieras, V.
    Staroslawska, E.
    Yardley, D. A.
    Davidson, N.
    Bachelot, T. D.
    Tassell, V. R.
    Huang, X.
    Kern, K. A.
    Romieu, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [36] Salvage capecitabine-leucovorine-vinorelbine combination chemotherapy in both anthracycline and taxane resistant metastatic breast cancer
    Stamatovic, L
    Jelic, S
    Susnjar, S
    Vasovic, S
    Nikolic-Tomasevic, Z
    Neskovic-Konstantinovic, Z
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S74 - S74
  • [37] A Three-Arm Randomized Phase II Study of Oral Vinorelbine Plus Capecitabine Versus Oral Vinorelbine and Capecitabine in Sequence Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines
    Campone, Mario
    Dobrovolskaya, Natalya
    Tjulandin, Serjei
    Chen, Shin-Chen
    Fourie, Sameul
    Mefti, Fawzia
    Konstantinova, Maria
    Lefresne, Florence
    Meheust, Nadege
    Jassem, Jacek
    BREAST JOURNAL, 2013, 19 (03): : 240 - 249
  • [38] Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
    Gabriel N. Hortobagyi
    Henry L. Gomez
    Rubi K. Li
    Hyun-Cheol Chung
    Luis E. Fein
    Valorie F. Chan
    Jacek Jassem
    Guillermo L. Lerzo
    Xavier B. Pivot
    Fernando Hurtado de Mendoza
    Binghe Xu
    Linda T. Vahdat
    Ronald A. Peck
    Pralay Mukhopadhyay
    Henri H. Roché
    Breast Cancer Research and Treatment, 2010, 122 : 409 - 418
  • [39] Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
    Hortobagyi, Gabriel N.
    Gomez, Henry L.
    Li, Rubi K.
    Chung, Hyun-Cheol
    Fein, Luis E.
    Chan, Valorie F.
    Jassem, Jacek
    Lerzo, Guillermo L.
    Pivot, Xavier B.
    Hurtado de Mendoza, Fernando
    Xu, Binghe
    Vahdat, Linda T.
    Peck, Ronald A.
    Mukhopadhyay, Pralay
    Roche, Henri H.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (02) : 409 - 418
  • [40] Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy
    Vahdat, L. T.
    Twelves, C.
    Allison, M. K.
    Cortes, J. A.
    Campone, M.
    Shuster, D. E.
    Wanders, J.
    Fang, F.
    Gurnani, R. D.
    Blum, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345